We are live on ! Find out more
SNOA icon

Sonoma Pharmaceuticals
SNOA

18 hedge funds and large institutions have $1.41M invested in Sonoma Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 18 → 18 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

61% less capital invested

Capital invested by funds: $3.58M → $1.41M (-$2.17M)

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Holders
18
Holders Change
–
Holders Change %
0%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$76.9K
2
Barclays
Barclays
United Kingdom
+$59.2K
3
RCM
Rotella Capital Management
Washington
+$56.2K
4
U
UBS
Switzerland
+$11.8K
5
VIA
Vantage Investment Advisors
Pennsylvania
+$8.88K

Top Sellers

Rank Fund Capital Flow
1
BA
Bard Associates
Illinois
-$586K
2
SC
Sophrosyne Capital
New York
-$522K
3
Morgan Stanley
Morgan Stanley
New York
-$482K
4
NL
NWAM LLC
Washington
-$107K
5
TRCT
Tower Research Capital (TRC)
New York
-$71K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$762K – – –
BRWA
2
B. Riley Wealth Advisors
Florida
$134K -$35.5K -12 -20%
NL
3
NWAM LLC
Washington
$117K -$107K -36 -46%
Jane Street
4
Jane Street
New York
$72K +$76.9K +26 New
BA
5
Bard Associates
Illinois
$59K -$586K -198 -90%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$59K – – –
RCM
7
Rotella Capital Management
Washington
$54K +$56.2K +19 New
Barclays
8
Barclays
United Kingdom
$54K +$59.2K +20 New
Morgan Stanley
9
Morgan Stanley
New York
$20K -$482K -163 -96%
U
10
UBS
Switzerland
$17K +$11.8K +4 +200%
Bank of America
11
Bank of America
North Carolina
$13K – – –
Bank of Montreal
12
Bank of Montreal
Ontario, Canada
$13K – – –
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$10K – – –
VIA
14
Vantage Investment Advisors
Pennsylvania
$9K +$8.88K +3 New
TRCT
15
Tower Research Capital (TRC)
New York
$6K -$71K -24 -92%
Wells Fargo
16
Wells Fargo
California
$4K – – –
PNC Financial Services Group
17
PNC Financial Services Group
Pennsylvania
$3K – – –
LTFS
18
Ladenburg Thalmann Financial Services
Florida
$2K – – –
NES
19
New England Securities
New York
$1K -$2.96K -1 Closed
Citigroup
20
Citigroup
New York
$1K – – –
SC
21
Sophrosyne Capital
New York
– -$522K -154 Closed
VKH
22
Virtu KCG Holdings
New York
– -$65K -19 Closed
Millennium Management
23
Millennium Management
New York
– -$43K -13 Closed

SNOA Hedge Fund Activity: Q2 2014 in Review

18 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2014, worth a combined $1.41M — down 61% from $3.58M a quarter earlier.

Fund positioning in SNOA was balanced in Q2 2014: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 5 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $76.9K. The largest seller was Bard Associates, cutting an estimated $586K.

  • 18 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2014, unchanged from Q1 2014.
  • Funds reported $1.41M of Sonoma Pharmaceuticals stock for Q2 2014, down 61% quarter-over-quarter.
  • 4 funds opened new Sonoma Pharmaceuticals positions in Q2 2014 and 4 closed out, a net change of 0 holders.
  • The largest Sonoma Pharmaceuticals buyer in Q2 2014 was Jane Street, an estimated $76.9K added.
  • The largest Sonoma Pharmaceuticals seller in Q2 2014 was Bard Associates, an estimated $586K sold.

Based on aggregated 13F filings for Q2 2014.